Paradromics

Executive Summary

Paradromics is a private neurotechnology company headquartered in Austin, Texas, developing the Connexus BCI—a high-data-rate, fully implantable brain-computer interface designed to enable communication for individuals with severe paralysis due to ALS, stroke, or spinal cord injury. Founded in 2015, the company leverages advanced neural recording technology to translate signals from individual neurons into digital commands, aiming to restore functional independence and quality of life for patients with profound motor impairments. The Connexus system is currently investigational, but its potential to decode rich neural signals positions Paradromics at the forefront of the BCI field, competing with other neurotech innovators like Neuralink and Synchron. Paradromics' approach addresses a critical unmet need in assistive communication technologies. The BCI market is projected to grow rapidly, driven by aging populations and increasing prevalence of neurodegenerative diseases. However, the company faces significant regulatory hurdles, manufacturing scale-up challenges, and competition from both non-invasive and less invasive solutions. While initial focus is on communication restoration, future applications could extend to motor control and sensory feedback. Successful clinical validation and FDA clearance will be key to unlocking market adoption. Given its early-stage status and the technical complexities of neural interfaces, Paradromics represents a high-risk, high-reward opportunity within the neurotechnology landscape.

Upcoming Catalysts (preview)

• Q4 2026FDA approval to initiate first-in-human clinical trial70% success
• 2027First patient implant with Connexus BCI system50% success
• 2026Announcement of strategic partnership or Series B funding80% success